Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALTA-2618 |
Synonyms | |
Therapy Description |
ALTA-2618 covalently binds to and inhibits AKT1 E17K, potentially resulting in decreased tumor growth (Cancer Res (2024) 84 (7_Supplement): LB173). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALTA-2618 | ALTA 2618|ALTA2618 | Akt1 Inhibitor 7 | ALTA-2618 covalently binds to and inhibits AKT1 E17K, potentially resulting in decreased tumor growth (Cancer Res (2024) 84 (7_Supplement): LB173). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06533059 | Phase I | ALTA-2618 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Recruiting | USA | 0 |